Search

Your search keyword '"Silling, Gerda"' showing total 8 results
Start Over Author "Silling, Gerda" Publication Year Range Last 3 years
8 results on '"Silling, Gerda"'

1. Early combination therapy of COVID-19 in high-risk patients

Author

Orth, Hans Martin, Flasshove, Charlotte, Berger, Moritz, Hattenhauer, Tessa, Biederbick, Kaja D., Mispelbaum, Rebekka, Klein, Uwe, Stemler, Jannik, Fisahn, Matthis, Doleschall, Anna D., Baermann, Ben-Niklas, Koenigshausen, Eva, Tselikmann, Olga, Killer, Alexander, de Angelis, Clara, Gliga, Smaranda, Stegbauer, Johannes, Spuck, Nikolai, Silling, Gerda, Rockstroh, Jürgen K., Strassburg, Christian P., Brossart, Peter, Panse, Jens P., Jensen, Björn-Erik Ole, Luedde, Tom, Boesecke, Christoph, Heine, Annkristin, Cornely, Oliver A., and Monin, Malte B.

Published
2024
Full Text
View/download PDF

3. Early combination therapy of COVID-19 in high-risk patients

Author

Orth, Hans Martin, primary, Flasshove, Charlotte, additional, Berger, Moritz, additional, Hattenhauer, Sandra Tessa, additional, Biederbick, Kaja D., additional, Mispelbaum, Rebekka, additional, Klein, Uwe, additional, Stemler, Jannik, additional, Fisahn, Matthis, additional, Doleschall, Anna D., additional, Baermann, Ben-Niklas, additional, Koenigshausen, Eva, additional, Tselikmann, Olga, additional, Killer, Alexander, additional, de Angelis, Clara, additional, Gliga, Smaranda, additional, Stegbauer, Johannes, additional, Spuck, Nikolai, additional, Silling, Gerda, additional, Rockstroh, Jürgen K., additional, Strassburg, Christian P., additional, Brossart, Peter, additional, Panse, Jens P., additional, Jensen, Björn-Erik Ole, additional, Luedde, Tom, additional, Boesecke, Christoph, additional, Heine, Annkristin, additional, Cornely, Oliver A., additional, and Monin, Malte B., additional

Published
2023
Full Text
View/download PDF

4. Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation

Author

Heinz, Amadeus T, primary, Calkoen, Friso G.J., additional, Derbich, Alexander, additional, Miltner, Lea, additional, Seitz, Christian, additional, Doering, Michaela, additional, Braun, Christiane, additional, Atar, Daniel, additional, Schumm, Michael, additional, Heubach, Florian, additional, Arendt, Anne-Marie, additional, Schulz, Ansgar, additional, Schuster, Friedhelm R, additional, Meisel, Roland, additional, Strahm, Brigitte, additional, Finke, Juergen, additional, Heineking, Beatrice, additional, Stetter, Susanne, additional, Silling, Gerda, additional, Stachel, Daniel, additional, Gruhn, Bernd, additional, Debatin, Klaus-Michael, additional, Foell, Juergen, additional, Schulte, Johannes H, additional, Woessmann, Wilhelm, additional, Mauz-Körholz, Christine, additional, Tischer, Johanna, additional, Feuchtinger, Tobias, additional, Handgretinger, Rupert, additional, and Lang, Peter, additional

Published
2023
Full Text
View/download PDF

5. Early Combination Therapy of COVID-19 in High-Risk Patients

Author

Orth, Hans-Martin, primary, Flaßhove, Charlotte, additional, Berger, Moritz, additional, Hattenhauer, Sandra Tessa, additional, Mispelbaum, Rebekka, additional, Biederbick, Kaja, additional, Klein, Uwe, additional, Stemler, Jannik, additional, Fisahn, Matthis, additional, Doleschall, Anna Dorottya, additional, Baermann, Ben-Niklas, additional, Königshausen, Eva, additional, Tselikmann, Olga, additional, Killer, Alexander, additional, de Angelis, Clara, additional, Gliga, Smaranda, additional, Stegbauer, Johannes, additional, Spuck, Nikolai, additional, Silling, Gerda, additional, Rockstroh, Jürgen K., additional, Strassburg, Christian Peer, additional, Brossart, Peter, additional, Panse, Jens Peter, additional, Jensen, Bjoern-Erik Ole, additional, Luedde, Tom, additional, Boesecke, Christoph, additional, Heine, Annkristin, additional, Cornely, Oliver A., additional, and Monin, Malte Benedikt Benedikt, additional

Published
2023
Full Text
View/download PDF

6. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Author

Platzbecker, Uwe, primary, Götze, Katharina S., additional, Kiewe, Philipp, additional, Germing, Ulrich, additional, Mayer, Karin, additional, Radsak, Markus, additional, Wolff, Thomas, additional, Chromik, Joerg, additional, Sockel, Katja, additional, Oelschlägel, Uta, additional, Haase, Detlef, additional, Illmer, Thomas, additional, Al-Ali, Haifa Kathrin, additional, Silling, Gerda, additional, Reynolds, Joseph G., additional, Zhang, Xiaosha, additional, Attie, Kenneth M., additional, Shetty, Jeevan K., additional, and Giagounidis, Aristoteles, additional

Published
2022
Full Text
View/download PDF

8. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility.

Author

Crysandt, Martina, Soysal, Hatice, Jennes, Eva, Holtick, Udo, Mrotzek, Matthias, Rehnelt, Susanne, Holderried, Tobias A. W., Wessiepe, Martina, Kunter, Uta, Wilop, Stefan, Silling, Gerda, Gecht, Judith, Beier, Fabian, Brümmendorf, Tim H., and Jost, Edgar

Subjects
PURE red cell aplasia, BLOOD group incompatibility, HEMATOPOIETIC stem cell transplantation, IMMUNOADSORPTION, RED blood cell transfusion, PLASMA exchange (Therapeutics), HEMAGGLUTININ
Abstract

Objective: ABO mismatch between donor and recipient occurs in 40% of allogeneic hematopoietic stem cell transplantations (HCT). Different strategies have been described to reduce isohemagglutinins (IHA) before HCT. We describe the effect of selective ABO immunoadsorption (ABO IA) on erythrocyte transfusion rate and the development of post‐transplant pure red cell aplasia (ptPRCA). Methods: 63 patients with major ABO incompatibility were retrospectively analyzed. Nine patients with major ABO incompatibility and high‐IHA titer were treated by ABO IA before HCT. We analyzed the need for transfusion and the occurrence of ptPRCA. We compared the outcome with patients treated by other methods to reduce IHA. Results: In all nine patients treated by ABO IA, IHA decreased in a median four times. PtPRCA occurred in one patient. The median number of transfusions was 8 (range: 0‐36) between d0 and d100. In 25 patients with high‐IHA titer without treatment or treated by other methods to reduce IHA, the need for transfusions was comparable. No difference in the incidence of ptPRCA was observed. Conclusions: Selective ABO IA is a feasible, safe, and effective method to reduce IHA before HCT in major ABO incompatibility. No effect on transfusion rate or ptPRCA compared to other strategies could be observed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results